NCT00460239View on ClinicalTrials.gov

Buprenorphine's Dose Response Curve

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Opioid-related Disorders
Interventions
DRUG

Buprenorphine

Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.

DRUG

Morphine

Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind

DRUG

Placebo

Intramuscular; double blind; once per week

Trial Locations (1)

21224

Johns Hopkins University (BPRU) Bayview Campus, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT00460239 - Buprenorphine's Dose Response Curve | Biotech Hunter | Biotech Hunter